Concepedia
Statistics
Publications
22
Citations
1.9K
H-Index
20
Active since
2002
Affiliations
Duke University(Current)
Duke University Hospital
Duke Medical Center
Portola Pharmaceuticals (United States)
Johnson & Johnson (United States)
Mark J. Karbarz is an author at Duke University specializing in pharmacology, life sciences, and enzymology.
Publications per year
2002–2020
A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa
Genmin Lu, Francis DeGuzman, Stanley J. Hollenbach et al. · Nature Medicine · 2013 · 697 citations
Medicine, Hematology, Pharmacology +16
MsbA Transporter-dependent Lipid A 1-Dephosphorylation on the Periplasmic Surface of the Inner Membrane
Xiaoyuan Wang, Mark J. Karbarz, Sara C. McGrath et al. · Journal of Biological Chemistry · 2004 · 126 citations · Full text
Life Sciences, Biochemistry, Microbiology +17
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal Of Rivaroxaban-Induced Anticoagulation In Healthy Subjects By Andexanet Alfa (PRT064445), An Antidote For Fxa Inhibitors
Mark Crowther, M. Manasar.Vandana, Michael Kitt et al. · Blood · 2013 · 115 citations
Medicine, Pharmacology, Pharmacotherapy +14
Periplasmic Cleavage and Modification of the 1-Phosphate Group of Helicobacter pylori Lipid A
An X. Tran, Mark J. Karbarz, Xiaoyuan Wang et al. · Journal of Biological Chemistry · 2004 · 95 citations · Full text
Thiadiazolopiperazinyl ureas as inhibitors of fatty acid amide hydrolase
John M. Keith, Richard L. Apodaca, Wei Xiao et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 92 citations · Full text
Life Sciences, Medicinal Chemistry, Pharmacology +8
1–5 of 22